Deltacel is under clinical development by Kiromic BioPharma and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Deltacel LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deltacel overview
Deltacel is under development for the treatment of non-small cell lung cancer and metastatic squamous cell carcinoma. It is administered through parenteral and intravenous route. It comprises of allogenic, non-viral, non-engineered gamma delta T-cells and is being developed based on ABBIE, non-viral genome editing technology and DIAMOND artificial intelligence and data mining platform. The therapeutic candidate was also under development for relapsed B cell acute lymphoblastic leukemia, non-small cell lung cancer and large B cell lymphoma.
Kiromic BioPharma overview
Kiromic BioPharma (Kiromic) discovers and develops immuno-oncology therapies using gene-editing technologies. The company is investigating ALEXIS PRO-1, an allogeneic GDT therapy product targeting PD-L1 for the treatment of solid tumor; and ALEXIS ISO-1, targeting an isoform of Mesothelin present on tumor cells. It utilizes Diamond, an artificial intelligence bioinformatics approach to identify new cancer immunological targets for T cells; and ABBIE, a non-viral genome editing mechanism to insert target DNA template information into the genome of a host cell. The company works in collaboration with biotechnology and pharmaceutical companies to develop its products. Kiromic is headquartered in Houston, Texas, the US.
For a complete picture of Deltacel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
